Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Group ACYW135 meningococcal conjugate vaccine is a quadrivalent vaccine developed by **Suzhou Weichao Biotechnology** for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W135. The vaccine consists of capsular polysaccharides from each of the four serogroups chemically conjugated to a carrier protein to enhance immunogenicity, particularly in infants and young children, by inducing a T-cell dependent immune response. It is formulated as a lyophilized powder for injection and is currently undergoing clinical evaluation (e.g., CTR20213130) for safety and immunogenicity in healthy populations ranging from 2 months to 55 years of age.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on group ACYW135 meningococcal conjugate vaccine (Suzhou Weichao Biotechnology).